Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Matthew Seavey"'
Autor:
Dareen Sarhan, Lara Rabah, Vikas Tahiliani, Anh M. Trinh, Rahul R. Jasuja, Eric P. Dixon, Matthew Seavey, Vivek Verma, Seema Gupta, Samir N. Khleif
Publikováno v:
Cancer Research. 82:2881-2881
TNFRSF25, also known as Death Receptor 3 (DR3), is a cell surface receptor of the tumor necrosis factor receptor superfamily (TNFRSF) which is expressed on T cells, innate lymphoid cells, and B cells. Upon binding with TL1A ligand, this co-stimulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d3293de0b15405d75f7d07c6aba7e1d
https://doi.org/10.1158/1538-7445.am2022-2881
https://doi.org/10.1158/1538-7445.am2022-2881
Publikováno v:
The Journal of Immunology. 186:164.3-164.3
Since therapeutic blockade of the cellular proteasome has previously demonstrated preclinical efficacy against inflammatory diseases, the evaluation of a novel, orally active proteosome inhibitor, CEP-18770, was tested in models of systemic lupus ery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3073dedbcfcaed7c73224ec9e3fcd19
https://doi.org/10.4049/jimmunol.186.supp.164.3
https://doi.org/10.4049/jimmunol.186.supp.164.3
Publikováno v:
The Journal of Immunology. 184:95.13-95.13
Passive immunotherapy is widely used in the treatment of cancer, however, active therapeutic vaccination is achieving increased effectiveness in clinic trials and in preclinical models of cancer. Our laboratory specializes in constructing therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6c3309e50d55dd45cb3c7cedf3d335a
https://doi.org/10.4049/jimmunol.184.supp.95.13
https://doi.org/10.4049/jimmunol.184.supp.95.13